Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy

Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat. Rev. Cancer, 12, 252, 10.1038/nrc3239 Waldman, 2020, A guide to cancer immunotherapy: from T cell basic science to clinical practice, Nat. Rev. Immunol., 20, 651, 10.1038/s41577-020-0306-5 Hirsch, 2017, Lung cancer: current therapies and new targeted treatments, Lancet, 389, 299, 10.1016/S0140-6736(16)30958-8 Doroshow, 2019, Immunotherapy in non-small cell lung cancer: facts and hopes, Clin. Cancer Res., 25, 4592, 10.1158/1078-0432.CCR-18-1538 Brahmer, 2018, The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC), J. Immunother. Cancer, 6, 1, 10.1186/s40425-018-0382-2 Michot, 2016, Immune-related adverse events with immune checkpoint blockade: a comprehensive review, Eur. J. Cancer, 54, 139, 10.1016/j.ejca.2015.11.016 Postow, 2018, Immune-related adverse events associated with immune checkpoint blockade, N. Engl. J. Med., 378, 158, 10.1056/NEJMra1703481 Hopkins, 2017, Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers, Br. J. Cancer, 117, 913, 10.1038/bjc.2017.274 Gibney, 2016, Predictive biomarkers for checkpoint inhibitor-based immunotherapy, Lancet Oncol, 17, e542, 10.1016/S1470-2045(16)30406-5 Taube, 2014, Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy, Clin. Cancer Res., 20, 5064, 10.1158/1078-0432.CCR-13-3271 Herbst, 2016, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A, Nature, 515, 563, 10.1038/nature14011 Abdel-Rahman, 2016, Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: a meta-analysis, Crit. Rev. Oncol. Hematol., 101, 75, 10.1016/j.critrevonc.2016.03.007 Grigg, 2016, PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?, J. Immunother. Cancer, 4, 1, 10.1186/s40425-016-0153-x Giommoni, 2021, Eosinophil count as predictive biomarker of immune-related adverse events (irAEs) in immune checkpoint inhibitors (ICIs) therapies in oncological patients, Immuno, 1, 253, 10.3390/immuno1030017 Davis, 2014, Eosinophils and cancer, Cancer Immunol. Res., 2, 1, 10.1158/2326-6066.CIR-13-0196 Moreira, 2017, Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy, Immunotherapy, 9, 115, 10.2217/imt-2016-0138 Weide, 2016, Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab, Clin. Cancer Res., 22, 5487, 10.1158/1078-0432.CCR-16-0127 Martens, 2016, Increases in absolute lymphocytes and circulating CD4+ and CD8+ T cells are associated with positive clinical outcome of melanoma patients treated with ipilimumab, Clin. Cancer Res., 22, 4848, 10.1158/1078-0432.CCR-16-0249 Delyon, 2013, Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival, Ann. Oncol., 24, 1697, 10.1093/annonc/mdt027 Gebhardt, 2015, Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab, Clin. Cancer Res., 21, 5453, 10.1158/1078-0432.CCR-15-0676 Gaba, 2015, Changes in blood eosinophilia during anti-PD1 therapy as a predictor of long term disease control in metastatic melanoma, J. Clin. Oncol., 33, 10.1200/jco.2015.33.15_suppl.9069 Nakamura, 2019, Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies, Jpn. J. Clin. Oncol., 49, 431, 10.1093/jjco/hyy201 Chu, 2020, Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors, Lung Cancer, 150, 76, 10.1016/j.lungcan.2020.08.015 Schindler, 2014, Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab, J. Clin. Oncol., 32, 10.1200/jco.2014.32.15_suppl.9096 Tanizaki, 2018, Peripheral blood biomarkers associated with clinical outcome in non–small cell lung cancer patients treated with nivolumab, J. Thorac. Oncol., 13, 97, 10.1016/j.jtho.2017.10.030 Lou, 2019, Hypereosinophilia in a patient with metastatic non-small-cell lung cancer treated with antiprogrammed cell death 1 (anti-PD-1) therapy, Immunotherapy, 11, 577, 10.2217/imt-2018-0128 Bagchi, 2021, Immune Checkpoint Inhibitors for the Treatment of Cancer: clinical Impact and Mechanisms of Response and Resistance, Annu. Rev. Pathol., 16, 223, 10.1146/annurev-pathol-042020-042741 Hogan, 2008, Eosinophils, Biological properties and role in health and disease, 38 Valent, 2012, Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes, J. Allergy Clin. Immunol., 130, 607, 10.1016/j.jaci.2012.02.019 Simon, 2019, Opposing roles of eosinophils in cancer, Cancer Immunol. Immunother., 68, 823, 10.1007/s00262-018-2255-4 Sakkal, 2016, Eosinophils in cancer: favourable or unfavourable?, Curr. Med. Chem., 23, 650, 10.2174/0929867323666160119094313 Mattei, 2020, Eosinophils in the tumor microenvironment, Adv. Exp. Med. Biol., 1273, 1, 10.1007/978-3-030-49270-0_1 Buder-Bakhaya, 2018, Biomarkers for clinical benefit of immune checkpoint inhibitor treatment-A review from the melanoma perspective and beyond, Front. Immunol., 9, 10.3389/fimmu.2018.01474 Robinson, 2022, Eosinophils and melanoma: implications for immunotherapy, Pigment Cell Melanoma Res, 35, 192, 10.1111/pcmr.13025 Fridman, 2012, The immune contexture in human tumours: impact on clinical outcome, Nat. Rev. Cancer, 12, 298, 10.1038/nrc3245 Munitz, 2004, Eosinophils: ‘new’ roles for ‘old’ cells, Allergy, 59, 268, 10.1111/j.1398-9995.2003.00442.x Hu, 2020, Tumor-associated tissue eosinophilia predicts favorable clinical outcome in solid tumors: a meta-analysis, BMC Cancer, 20, 1, 10.1186/s12885-020-06966-3 Carretero, 2015, Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8 + T cells, Nat. Immunol., 16, 609, 10.1038/ni.3159 Simson, 2007, Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance, J. Immunol., 178, 4222, 10.4049/jimmunol.178.7.4222 Gatault, 2012, Involvement of eosinophils in the anti-tumor response, Cancer Immunol. Immunother., 61, 1527, 10.1007/s00262-012-1288-3 Lotfi, 2008, Eosinophils induce DC maturation, regulating immunity, J. Leukoc. Biol., 83, 456, 10.1189/jlb.0607366 Fernández-Aceñero, 2000, Prognostic influence of tumor-associated eosinophilic infiltrate in colorectal carcinoma, Cancer, 88, 1544, 10.1002/(SICI)1097-0142(20000401)88:7<1544::AID-CNCR7>3.0.CO;2-S Ishibashi, 2006, Tumor-associated tissue eosinophilia in human esophageal squamous cell carcinoma, Anticancer Res, 26, 1419 Prizment, 2016, Tumor eosinophil infiltration and improved survival of colorectal cancer patients: iowa Women's Health Study, Mod. Pathol., 29, 516, 10.1038/modpathol.2016.42 Krishnan, 2020, A retrospective analysis of eosinophilia as a predictive marker of response and toxicity to cancer immunotherapy, Futur. Sci. OA, 6, 10.2144/fsoa-2020-0070 Soyano, 2018, Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies, J. Immunother. Cancer, 6, 1, 10.1186/s40425-018-0447-2 Das, 2019, Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors, J. Immunother. Cancer, 7, 1, 10.1186/s40425-019-0805-8 Riudavets, 2018, Correlation between immune-related adverse events (irAEs) and efficacy in patients with solid tumors treated with immune-checkpoints inhibitors (ICIs), J. Clin. Oncol., 36, 10.1200/JCO.2018.36.15_suppl.3064 Grangeon, 2019, Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer, Clin. Lung Cancer, 20, 201, 10.1016/j.cllc.2018.10.002 Sato, 2018, Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab, Lung Cancer, 115, 71, 10.1016/j.lungcan.2017.11.019